Table 1. Clinical information from the eligible trials in the meta-analysis.
| Included studies | Tumor stage/KPS | Patients Con/Exp | Therapeutic regimen | Dosage of kanglaite | Parameter types | |
|---|---|---|---|---|---|---|
| Experimental | Control (drugs) | |||||
| Ao, M. (2017) | ≥60 | 38/38 | Con+ kanglaite1 | TACE (DDP, 5-Fu, E-ADM) | 20 g/time, 1 time/day | ORR, DCR, AE |
| Feng, Y.Z. (2001) | II–IV | 21/11 | Con+KLT1 | TAE | 20 g/time, 1 time/day | ORR, DCR, IF |
| Hu, J.B. (2003) | II–IV | 25/31 | Con+KLT1 | TACE (DDP, 5-Fu, THP) | 20 g/time, 1 time/day | ORR, DCR, AE, CS, AFP, QoL |
| Jiang, Y.B. (2006) | I–III | 51/105 | Con+KLT1 | TACE (DDP, 5-Fu, ADM) | 20 g/time, 1 time/day | ORR, DCR, CS, QoL |
| Li, D.J. (2009) | II–III | 32/30 | Con+KLT2 | TACE (DDP, 5-Fu, ADM) | 2.7 g /time, 4 times/day | OS, ORR, DCR, AE, AFP, QoL |
| Li, M. (2015) | II-III | 23/24 | Con+KLT1 | CT (Oxaliplatin) | 20 g/time, 1 time/day | OS, ORR, DCR, IF, CS, QoL |
| Li, Y. (2014) | I–IV | 75/75 | Con+KLT1 | CT (Meccnu, ADM, 5-Fu) | 20 g/time, 1 time/day | OS, ORR, DCR, AE, QoL |
| Liang, S.M. (2006) | II-III | 25/31 | Con+KLT1 | TAE | unknown | ORR, DCR, CS, AFP |
| Lu, D.P. (2017) | Unknown | 43/51 | Con+KLT1 | TACE (Oxaliplatin, 5-Fu) | 20 g/time, 1 time/day | OS, ORR, DCR, QoL |
| Lu, H. (2006) | I–III | 24/24 | Con+KLT1 | TACE (DDP, 5-Fu, MMC) | 20 g/time, 1 time/day | OS, ORR, DCR, AE, QoL |
| Lv, D.Z. (2004) | II–III | 38/38 | Con+KLT1 | TACE (unknown), SST | 20 g/time, 1 time/day | IF, CS, QoL |
| Ma, W.L. (2017) | Unknown | 43/43 | Con+KLT1 | CT (FOLFOX) | 20 g/time, 1 time/day | ORR, DCR, IF |
| Qin, G.Y. (1998) | Unknown | 20/18 | Con+KLT1 | TACE (DDP, 5-Fu, THP) | 10-20 g/time, 1 time/day | ORR, DCR, CS |
| Qin, Y.T. (2001) | Unknown | 42/52 | Con+KLT1 | SST | 20 g/time, 1 time/day | IF |
| Shao, L. (2017) | II–III | 25/25 | Con+KLT1 | SRT | 20 g/time, 1 time/day | ORR, AE, QoL |
| Wang, C.H. (2001) | I–III | 50/50 | Con+KLT1 | TACE (DDP, ADM, HCPT) | 10 g/time, 1 time/day | ORR, DCR |
| Wang, X.F. (2012) | III–IV | 24/34 | Con+KLT1 | TACE (unknown) FOLFOX | 10 g/time, 1 time/day | ORR, AE, QoL |
| Wei, Q.C. (2009) | Unknown | 24/24 | Con+KLT1 | SST | 10 g/time, 1 time/day | QoL |
| Wu, D.H. (2009) | II–III | 30/30 | Con+KLT1 | CT (Oxaliplatin, FUDR) | 20 g/time, 1 time/day | ORR, DCR, AE, CS, QoL |
| Wu, J.L. (2015) | Unknown | 60/60 | Con+KLT1 | TACE (unknown) | 10 g/time, 1 time/day | ORR, DCR, QoL |
| Xi, D.S. (2001) | I–III | 20/20 | Con+KLT1 | CT (E-ADM, 5-Fu, HCPT, ACTD) | 20 g/time, 1 time/day | ORR, DCR, AE |
| Xu, J. (2018) | Unknown | 54/54 | Con+KLT1 | CT (Meccnu, ADM, 5-Fu) | 20 g/time, 1 time/day | ORR, DCR |
| Xu, X.H. (2010) | II–III | 37/38 | Con+KLT1 | CT (Capecitabine) | 20 g/time, 1 time/day | OS, ORR, DCR, AE, CS |
| Yang, T. (2013) | ≥60 | 30/60 | Con+KLT1 | TACE (DDP, 5-Fu, E-ADM) | 10 g/time, 1 time/day | ORR, DCR, AE, CS, QoL |
| Ye, X. (2003) | III-IV | 17/19 | Con+KLT1 | TACE (DDP, 5-Fu, ADM, MMC) | 20 g/time, 1 time/day | ORR, DCR, AE, CS, AFP, QoL |
| Yin, R.R. (2009) | Unknown | 32/40 | Con+KLT1 | TACE (unknown) | 10 g/time, 1 time/day | ORR, DCR |
| Yu, Z.H. (2016) | ≥50 | 20/20 | Con+KLT1 | Thalidomide | 20 g/time, 1 time/day | OS, ORR, DCR, AE, QoL |
| Zhang, Y. (2012) | >50 | 31/31 | Con+KLT1 | SST | 10 g/time, 1 time/day | AFP, QoL |
| Zhang, Y.J. (2017) | II–III | 48/49 | Con+KLT1 | TACE (DDP, 5-Fu, ADM, MMC) | 20 g/time, 1 time/day | ORR, DCR, AE, AFP, QoL |
| Zhou, S.F. (2018) | III–IV | 54/54 | Con+KLT1 | Sorafenib | 20 g/time, 1 time/day | ORR, DCR, IF |
| Zhu, X.F. (2006) | I–IV | 40/40 | Con+KLT1 | TACE (DDP, 5-Fu, THP) | 20 g/time, 1 time/day | ORR, DCR, CS, QoL |
Con, control group (CTs alone group); Exp, experimental group (CTs and kanglaite group). Abbreviations: ACTD, actinomycin D; ADM, adriamycin; AE, adverse event; CF, calcium folinate; CS, clinical symptom; DDP, cisplatin; E-ADM, epirubicin; FOLFOX, qxaliplatin+CF+5-Fu; HCPT, hydroxycamptothecin; IF, immune function; MMC, mitomycin C; ORR, overall response rate; THP, pirarubicin; 5-Fu, 5-Fluorouracil.
1Kanglaite injection.
2Kanglaite capsules.